June 29–July 3, 2026: The Shanghai Stock Exchange said it imposed self‑regulatory measures in 366 abnormal‑trading cases (including manipulative boosting/suppression and false orders). The exchange placed heightened surveillance on volatile names including Zhongchuan Teqi, Changyingtong and Yunzhong Technology and on high‑premium funds such as Caitong Fuxin LOF and Global Chip LOF. It launched special reviews of 29 major listed‑company events and reported two suspected illegal‑activity case lead

UBS said after a virtual healthcare roadshow with Xinda Biologics (01801.HK) management that Q2 product sales momentum remains solid and is being treated as a new normal, supported by an innovative product mix and high unmet demand. Management said tightening of online channels for GLP‑1s has not created pressure and cited healthy category demand during the recent 618 e‑commerce event. UBS has included Pfizer licensing income and sales of partner asset Abesili in its model but raised 2026–28 R&D expense forecasts to reflect collaboration commitments, trimming EPS estimates for 2026–2028 to 1.12, 2.41 and 3.42 yuan from 1.13, 2.91 and 4.41 yuan. UBS slightly raised its target price to HK$124.1 (from HK$124) and reiterated an upgrade/buy rating.

July 3 — Alibaba DAMO Academy, with Renmin University of China and the University of Chinese Academy of Sciences, released its first superconducting-material discovery AI agent, Elements Claw. The system predicted about 68,000 candidate superconductors; four novel materials have been synthesized and experimentally confirmed to exhibit superconductivity, and all related data have been made publicly available.